Home > Business Cases > Future clinical safety and drug metabolites
Future clinical safety and drug metabolites
Situation
A company is exploring a NCE which is a dual inhibitor of enzymes neprilysin (NEP) and aminopeptidase-N (APN), involved in pain. Metabolites of the compound are known to bind to 3 other targets not involved in pain pathways. Besides, the company has microarray and proteomics data in response to drug and metabolites exposure. The company wants to explore future clinical safety and new indications of the compound.
Anaxomics Strategy
Anaxomics created the biological network around known targets of compound and metabolites, including 1000+ nodes and milions of interactions. We developed a model that explained the observed behaviour of more than 100 known drugs whose targets where contained in the network, and that explained the behaviour of the additional microarray proteomics information.
Solution and Practical Use
Using the same network and model that explained the behaviour of known drugs, we predicted that the Client's compound was likely to produce cardiotox, specifically QTc prolongation problems, caused by the interaction of metabolites with non-pain targets. Client tested compound extensively in murine cardiotox models and found out potential cardiotox. NCE was discarded.
Please, contact us here to request more information.
